Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Conditions:   Metastatic Breast Cancer;   Breast Cancer Interventions:   Drug: Neratinib;   Drug: Capmatinib Sponsors:   M.D. Anderson Cancer Center;   Celcuity, Inc.;   Novartis;   Puma Biotechnology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials